Firefly Neuroscience, Inc. Common Stock
AIFFFirefly Neuroscience, Inc. is a biotechnology company focused on developing innovative neural interface technologies. The company aims to create products that facilitate communication between the brain and electronic devices, with a focus on advancing treatments for neurological disorders and enhancing human capabilities through neurotechnology.
Company News
Firefly Neuroscience researchers have developed a new method to accurately differentiate between subjective cognitive decline (SCD), mild cognitive impairment (MCI), and dementia in Alzheimer's patients using a combination of EEG/ERP and volumetric MRI data.
Firefly Neuroscience, an AI company, has acquired Evoke Neuroscience, a medical device company, to expand its proprietary database, patent portfolio, and commercial reach. The acquisition marks a significant step towards Firefly's goal of building a foundation model of the human brain.
Firefly Neuroscience, Inc. has received $8.8 million from the exercise of warrants, which will be used for general working capital purposes, including the development of its FDA-cleared Brain Network Analytics (BNAâ„¢) technology platform.
Firefly Neuroscience, an AI company developing solutions for brain health, has been accepted into the NVIDIA Connect program. This will provide Firefly with technical resources to support its initiative to build a proprietary foundation model of the human brain using its FDA-cleared BNAâ„¢ technology platform.
Firefly Neuroscience, a Nasdaq-listed AI company, announced its Q3 2024 financial results and provided updates on its partnerships with pharmaceutical companies like Bright Minds Bioscience, Novartis, and Takeda to advance its Brain Network Analytics (BNA) technology for neurological and mental disorder treatments.
